Trovagene Inc, San Diego, plans to collaborate with a pharmaceutical company to evaluate Trovagene’s proprietary, urine-based, cell-free DNA technology for the detection of certain epidermal growth factor receptor (EGFR) mutations associated with lung cancer.
“The ability to noninvasively monitor real-time EGFR mutations changes in lung cancer patients represents the potential to obtain greater guidance for treatment decisions,” says Antonius Schuh, PhD, CEO, Trovagene.
Lung cancer is the most prevalent cancer in the United States, with more than 225,000 new cases diagnosed annually. EGFR mutations are present in 10% to 35% of lung cancers, and these mutations frequently occur during the course of therapy, affecting response to treatment and/or prognosis.
“This study will help us further evaluate Trovagene’s technology as an alternative for mutation monitoring in lung cancer, where tissue biopsies are often challenging to obtain,” says Mark Erlander, the company’s chief scientific officer.